

4/7/2023

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Incyte Corporation is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 4/6/2023. The new products being launched are:

50881-0006-03: Zynyz Intravenous Solution 500mg/ 20ml

Sincerely,

Amy Hall

AVP & Head of Market Access, Distribution and Patient Access Services - Oncology